Abstract LB_A01: Rapidly cleared MCL1 inhibitor TTX-810 showing robust efficacy in preclinical tumor models with no effects on cardiomyocytes in vitro and in vivo
Ulrike Rauh(Centro de Pesquisas Oncológicas), Todd R. Golub(Broad Institute), Georgios Kosmidis(Netherlands Consortium for Healthy Ageing), Virendar K. Kaushik(Broad Institute), Sabine Pilari, Weiqun Zhang(Broad Institute), Kai Thede(Nuvisan (Germany)), Douglas S. Daniels(Broad Institute), Michael H. Serrano‐Wu(Broad Institute), Stefan Kaulfuß(Pfizer (Germany)), Guo Wei(Broad Institute), G. Poncet-Montange(Broad Institute), Brian Hubbard, Christopher T. Lemke(Broad Institute)
Cited by 1
Related Papers
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
|Proceedings of the National Academy of Sciences|2005|56.5k
Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring
|Science|1999|11.6k
PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes
|Nature Genetics|2003|10.6k
The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease
|Science|2006|5.5k
Copper induces cell death by targeting lipoylated TCA cycle proteins
|Science|2022|4.6k